Category: Antibodies

Novel Antibody Therapies: Addressing Unmet Needs for Oncological Disorders

Antibodies are key components of the immune system that bind to specific markers on cells or tissues, thereby offering first line of defense against multiple disorders. The novel antibody therapies include different classes of antibodies, that are responsible for killing or inhibiting disease-causing agents. These therapies target proteins that are expressed on the surface of

Glycoengineered Antibodies and Fc Protein – Virtue of enhanced effector functions

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry.[1] In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025.[2] Further, within the antibody therapeutics industry, engineered

Antibody Drug Conjugates – A Potential Tool Against Cancer

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies. ADC Therapeutics are engineered therapies comprised of monoclonal antibodies

Genomic Data Management: Opportunities for Blockchain Platform Providers

It is estimated that, by 2025, around 15% of the world’s population will have had their genomes sequenced, resulting in the generation of several zettabytes of data. However, currently, there are not many reliable and secure data management resources that offer secure storage, seamless exchange of information, and a reliable transaction platform, for large volumes

ADC Manufacturing: Current Landscape, Growth Opportunities and Future Market Outlook

Antibody drug conjugates (ADCs) are one of the most popular classes of targeted therapeutic agents and have captured the attention of both large and small pharmaceutical companies, and academic / research institutions across the world. Owing to the fact that these novel conjugates are highly potent toxic molecules, their manufacturing requires elaborate technical capabilities, along

Antibody Discovery: The Rise of Services and Platform Providers

Owing to several beneficial features, such as high specificity, and a favorable safety profile, antibody (Ab) discovery based pharmacological interventions, with 79 molecules approved till date and over 200 molecules in the preclinical / discovery stages, presently represent the largest class of biologics. The discovery of antibodies is a long, arduous and cost intensive process.

Bispecific Antibodies: Current Landscape, Market Trends and Future Outlook

Bispecific antibodies have demonstrated the capability to address the existing challenges associated with monoclonal antibodies, such as high manufacturing costs, limited applicability in assays and the general lack of understanding of precise in vivo mechanisms of action. The ‘Bispecific Antibody Therapeutics Market (3rd Edition), 2017-2030’ report provides a comprehensive study of the current landscape of bispecific antibodies, featuring an